Stock events for Relmada Therapeutics, Inc. (RLMD)
The past six months have seen significant volatility for Relmada Therapeutics' stock, including a substantial increase of 255.97%. In February 2025, the stock plummeted to a 52-week low, and the company faced potential delisting from Nasdaq. The Phase 3 trial for REL-1017 was deemed futile, leading to stock rating downgrades. The company reported reduced losses in Q2 and Q3 2025 and presented favorable Phase 2 data for NDV-01 in December 2025. In February/March 2026, the stock showed an upward trend, and LUCID CAPITAL MARKETS initiated coverage with a "Buy" recommendation in March 2026.
Demand Seasonality affecting Relmada Therapeutics, Inc.’s stock price
As a clinical-stage biotechnology company, Relmada Therapeutics, Inc. does not exhibit traditional demand seasonality for its products or services. The demand for its product candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for the treatments once they are commercialized.
Overview of Relmada Therapeutics, Inc.’s business
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on addressing diseases of the central nervous system. The company develops new chemical entities and novel versions of drug products to meet high unmet medical needs. Its major product candidates include Esmethadone for depression, NDV-01 for bladder cancer, Sepranolone for compulsive behavior disorders, and REL-P11 for metabolic disease.
RLMD’s Geographic footprint
Relmada Therapeutics, Inc. is headquartered in Coral Gables, Florida, and operates as a clinical-stage biotechnology company in the United States. Information regarding a broader international geographic footprint or specific market reach beyond the U.S. is not readily available.
RLMD Corporate Image Assessment
Relmada Therapeutics' brand reputation in the past year has likely been significantly impacted by the volatility of its stock and the outcome of its clinical trials. The stock's plummet to a 52-week low and the potential delisting concerns in early 2025, coupled with the futility declaration of the Phase 3 trial for REL-1017, would have negatively affected its reputation among investors and potentially in the broader biopharmaceutical community. However, more recent positive developments, such as favorable Phase 2 data for NDV-01 and new "Buy" recommendations from analysts in early 2026, could contribute to a rebuilding of confidence and a more positive perception.
Ownership
Approximately 69.43% of Relmada Therapeutics' stock is held by institutional shareholders, 4.82% by insiders, and 25.75% by retail investors. Major institutional owners include Janus Henderson Group Plc and Squadron Capital Management LLC. The largest individual shareholder is Sergio Traversa, who owns 1.30 million shares, representing 1.77% of the company.
